Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma

There is a need to improve the effectiveness of radiotherapy (RT) in hepatocellular carcinoma (HCC). Therefore, the purpose of this study was to explore the efficacy and toxicity of the anti-microtubule agent Vinorelbine as a radiosensitizer in HCC. The radio sensitivity of 16 HCC patient-derived xe...

Full description

Bibliographic Details
Main Authors:	Kheng Wei Yeoh, Aldo Prawira, Muhammad Zafrie Bin Saad, Kok Ming Lee, Eric Ming Hon Lee, Gee Keng Low, Mohamed Hakim Bin Mohd Nasir, Jun Hao Phua, Wendy Wan Li Chow, Iris Jiu Hia Lim, Yusnita Binte Omar, Rebecca Zhi Wen Ho, Thi Bich Uyen Le, Thanh Chung Vu, Khee Chee Soo, Hung Huynh
Format:	Article
Language:	English
Published:	MDPI AG 2020-04-01
Series:	Cancers
Subjects:	hepatocellular carcinoma radiotherapy radio sensitization vinorelbine DNA repair cost-effectiveness
Online Access:	https://www.mdpi.com/2072-6694/12/4/872

Similar Items

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2022-01-01)

Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma
by: Valentina Rinaldi, et al.
Published: (2023-11-01)

Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
by: Wai Har Ng, et al.
Published: (2024-01-01)

Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer
by: Yang ZHOU, et al.
Published: (2015-06-01)

Vinorelbine plus Oxaliplatin versus Vinorelbine plus Cisplatin for Advanced Non-small Cell Lung Cancer: A Systematic Review
by: Kehu YANG, et al.
Published: (2010-02-01)

The role of autophagy in human lung cancer cell line A549 induced by Vinorelbine
by: Xiao FU, et al.
Published: (2008-06-01)

The Effect and Mechanism of Vinorelbine on Cisplatin Resistance  of Human Lung Cancer Cell Line A549/DDP
by: Chunsheng QI, et al.
Published: (2014-02-01)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
by: Rong-Sheng Qin, et al.
Published: (2018-10-01)

Gemcitabine Combined with Vinorelbine in the Treatment of Refractory Patients with Advanced Non-small Cell Lung Cancer: A Multi-center Retrospective Study
by: Shun LU, et al.
Published: (2012-09-01)

Prevention of vasculitis and vascular pain by side route administration of vinorelbine: A case report
by: Shunichi Ishii, et al.
Published: (2023-05-01)

Synergistic anti-cancer and attenuation effects of thymosin on chemotherapeutic drug vinorelbine in tumor-bearing zebrafish
by: Shuai Wang, et al.
Published: (2023-06-01)

Effect of sCD40L Combined with Vinorelbine on Lung Adenocarcinoma Cell A549
by: Shan LIU, et al.
Published: (2010-07-01)

Effect of surface modification on the In vitro protein adsorption and cell cytotoxicity of vinorelbine nanoparticles
by: Nandhakumar Sathyamoorthy, et al.
Published: (2017-01-01)

N-acetylcysteine attenuates the incidence of phlebitis induced by carbomer/vinorelbine gel
by: Hongyu Zhang, et al.
Published: (2023-11-01)

Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile
by: Hasan Alsharoh, et al.
Published: (2023-12-01)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

Efficacy of Gemcitabine and Vinorelbine in First-line Treatment  with Advanced Non-small Cell Lung Cancer: A Multicentre Retrospective Study
by: Yongfeng YU, et al.
Published: (2012-05-01)

A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer
by: Guanghui GAO, et al.
Published: (2009-01-01)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
by: Dean A. Fennell, et al.
Published: (2022-06-01)

Two years progression-free survival under vinorelbine metronomic therapy of a patient with metastatic epithelioid hemangioendothelioma
by: Stavros Anevlavis, et al.
Published: (2022-04-01)

Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC
by: Pal K, et al.
Published: (2019-07-01)

Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib
by: V. Sgroi, et al.
Published: (2018-01-01)

Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective against Tumor Re-Challenge
by: Stefania Orecchioni, et al.
Published: (2023-03-01)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
by: Anjie Zhu, et al.
Published: (2021-08-01)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
by: Yue Chai, et al.
Published: (2023-08-01)

Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies
by: Fausto Petrelli, et al.
Published: (2011-12-01)

GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER
by: Deyan Davidov
Published: (2008-09-01)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
by: F. F. Pepe, et al.
Published: (2022-09-01)

Risk factors for venous irritation in patients receiving vinorelbine: a retrospective study
by: Yoshihito Morimoto, et al.
Published: (2018-10-01)

Clinical Observation of Metronomic Oral Vinorelbine Monotherapy as First-line Treatment on Elderly Patients with Advanced Non-small Cell Lung Cancer
by: LIN Jinlan, et al.
Published: (2018-11-01)

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
by: Zhen-zhou SHEN, et al.
Published: (2010-02-01)

A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer
by: Guolan Wu, et al.
Published: (2019-07-01)

Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma
by: Malvika Arya, et al.
Published: (2018-05-01)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
by: Slavomir Krajnak, et al.
Published: (2023-01-01)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
by: Barbara Adamo, et al.
Published: (2019-09-01)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2021-04-01)

Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI
by: Katrina M. Ingley, et al.
Published: (2019-09-01)

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
by: Xue Wang, et al.
Published: (2023-04-01)

A Novel Active Targeting Preparation, Vinorelbine Tartrate (VLBT) Encapsulated by Folate-Conjugated Bovine Serum Albumin (BSA) Nanoparticles: Preparation, Characterization and in Vitro Release Study
by: Xinyang Yu, et al.
Published: (2012-11-01)

Discovery of Novel Agents on Spindle Assembly Checkpoint to Sensitize Vinorelbine-Induced Mitotic Cell Death against Human Non-Small Cell Lung Cancers
by: Ya-Ching Chang, et al.
Published: (2020-08-01)